TrialBMC nephrology2019

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.

Hayley Bennett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.